http://repositorium.sdum.uminho.pt/bitstream/1822/48763/1/1-s2.0-S037026931200857X-main.pdf

Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC

https://digital.csic.es/bitstream/10261/108964/1/experiment%20at%20the%20LHC.pdf

Observation of a new boson at a mass of 125 GeV with the CMS experiment at the LHC

Background The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical computed tomography (CT) altered the landscape of lung-cancer screening, with studies indicating that low-dose CT detects many tumors at early stages. The National Lung Screening Trial (NLST) was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer. Methods From August 2002 through April 2004, we enrolled 53,454 persons at high risk for lung cancer at 33 U.S. medical centers. Participants were randomly assigned to undergo three annual screenings with either low-dose CT (26,722 participants) or single-view posteroanterior chest radiography (26,732). Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. Results The rate of adherence to screening was more than 90%. The rate of positive screening tests was 24.2% with low-dose CT and 6.9% with radiography over all three rounds. A total of 96.4% of the positive screening results in the low-dose CT group and 94.5% in the radiography group were false positive results. The incidence of lung cancer was 645 cases per 100,000 person-years (1060 cancers) in the low-dose CT group, as compared with 572 cases per 100,000 person-years (941 cancers) in the radiography group (rate ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.23). There were 247 deaths from lung cancer per 100,000 person-years in the low-dose CT group and 309 deaths per 100,000 person-years in the radiography group, representing a relative reduction in mortality from lung cancer with low-dose CT screening of 20.0% (95% CI, 6.8 to 26.7; P=0.004). The rate of death from any cause was reduced in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2 to 13.6; P=0.02). Conclusions Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385.).

/pdf/reduced-lung-cancer-mortality-with-low-dose-computed-315bk0rtxu.pdf

Reduced lung-cancer mortality with low-dose computed tomographic screening.

https://www.hal.inserm.fr/inserm-00561753/document

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

The ATLAS detector as installed in its experimental cavern at point 1 at CERN is described in this paper. A brief overview of the expected performance of the detector when the Large Hadron Collider begins operation is also presented.

The ATLAS Experiment at the CERN Large Hadron Collider

5510 Background: Vandetanib (V) is an oral inhibitor of VEGFR, EGFR and RET signaling. Methods: Eligible patients (pts) with previously untreated, unresected HNSCC received once-daily V (starting d...

Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).

Molecularly targeted therapy: When to stop and when to continue?

Twenty years ago, Pearse identified a group of endocrine cells sharing multiple morphological and biochemical features. He named them APUD cells (Amine Precurser Uptake and Decarboxylation) because of their amine-handling properties, one of their main functions being their ability to take up and decarboxylate relatively simple amino precursor substances, such as dihydroxyphenylanaline (DOPA) and 5-hydroxytryptamine (5-HT), thus producing biogenic amines [1]. Today, these cells are known as neuro-endocrine (NE) cells and the APUD system as the Dispersed Neuroendocrine System (DNS), currently consisting of more than 40 different cell types.

Neuroendocrine characteristics in malignant lung tumors: Implications for diagnosis, treatment, and prognosis

11076 Background: High EGFR gene copy number is associated with efficacy in NSCLC patients (pts) receiving combined chemotherapy and cetuximab (S0342). EGFR protein is typically overexpressed in tu...

SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC)

Fred R. Hirsch

Papers

Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).

Molecularly targeted therapy: When to stop and when to continue?

Neuroendocrine characteristics in malignant lung tumors: Implications for diagnosis, treatment, and prognosis

SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC)

Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer